Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor
Status:
Completed
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for
malignant tumors (especially hematological tumors). Like other immunotherapies, the basic
principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen
receptor (car) is the core component of car-t, which endows T cells with the ability to
recognize tumor antigens in an independent manner, which enables car modified T cells to
recognize a wider range of targets than natural T cell surface receptors (TCR). The basic
design of car includes a tumor associated antigen binding region (usually derived from scFv
segment of monoclonal antibody antigen binding region), transmembrane region and
intracellular signal region. The selection of target antigen is a key determinant for the
specificity and effectiveness of car and the safety of genetically modified T cells.
BCMA is a specific surface protein of B lymphocytes, which plays an important role in the
development, proliferation and differentiation of B cells. BCMA is highly expressed in
malignant mm plasma cells and provides a large number of anti apoptotic signals, which makes
bcam an ideal target in targeted immunotherapy. At present, a variety of immunotherapy
strategies targeting BCMA are being carried out in laboratory and clinical practice, which
have achieved encouraging therapeutic effects in multiple myeloma and effectively promoted
the development of targeted immunotherapy.